Cagrilintide is a novel, long-acting, acylated insulin analog under development as a non-selective agonist of the amyloid receptor (AMYR) and calcitonin G protein-coupled receptor (CTR). It has been shown to significantly reduce body weight and food intake. cagrilintide’s mechanism of action is different from that of existing weight-loss medications, and has great potential to be used as a novel and effective drug in the treatment of obesity, which is expected to change the current landscape of obesity patients and provide new options for clinicians.
Cagrilitinide peptide benefits
Professor David C W Lau and his team from Cumming School of Medicine, University of Calgary, Canada, published a heavyweight article in the top medical journal (The Lancet), reporting the preliminary efficacy and safety tolerability of cagrilintide applied to weight management in overweight and obese people. The results showed that once-weekly injections of cagrilintide, as an adjunct to lifestyle interventions, resulted in an average weight loss of up to 11.5 kg after 26 weeks and were safely tolerated.
Cagrilitinide peptide Dosage
The dose range for Cagrilitinide is 0.16 to 4.5 mg subcutaneously once weekly.
Cagrilintide peptide Side Effects
In terms of safety, the most common adverse events were gastrointestinal dysfunction (e.g., nausea, constipation, and diarrhea) and administration site reactions. A higher proportion of subjects injected with cagrilintide 0.3 mg-4.5 mg experienced gastrointestinal adverse events (41%-63% vs. 32%), primarily nausea (20%-47% vs. 18%), compared with the placebo group.
More Introduction:https://en.wikipedia.org/wiki/Cagrilintide
